Clinical Trials Browser

Completed × INDUSTRY × devimistat × Clear all

NCT04593758 2023-05-24

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Phase 1/2 Completed

Sarcoma, Clear Cell

NCT03504423 2023-01-03

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Phase 3 Completed

528 enrolled 11 charts

Gastrointestinal

Pancreatic Cancer Metastatic

NCT00741403 2016-12-29

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Phase 1 Completed

Lymphoma, Neoplasm Metastasis, Neoplasms, Recurrence